Skip to Content
Merck
CN

H0100100

Haloperidol decanoate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Decanoic acid 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl ester

Sign Into View Organizational & Contract Pricing

About This Item

Empirical Formula (Hill Notation):
C31H41ClFNO3
CAS Number:
Molecular Weight:
530.11
UNSPSC Code:
41116107
NACRES:
NA.24
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

pharmaceutical primary standard

API family

haloperidol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Fc1ccc(cc1)C(=O)CCCN2CCC(CC2)(OC(=O)CCCCCCCCC)c3ccc(cc3)Cl

InChI

1S/C31H41ClFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3

InChI key

GUTXTARXLVFHDK-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Haloperidol decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Long term results of unilateral posteroventral pallidotomy for antipsychotic drug induced tardive dyskinesia.
M W P M Lenders et al.
Journal of neurology, neurosurgery, and psychiatry, 76(7), 1039-1039 (2005-06-21)
Hidenobu Suzuki et al.
Human psychopharmacology, 27(5), 470-475 (2012-09-25)
This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol
Ira D Glick et al.
The Journal of clinical psychiatry, 66(5), 638-641 (2005-05-14)
To compare the long-term efficacy and tolerability of oral quetiapine with those of intramuscular haloperidol. Patients with DSM-IV-diagnosed schizophrenia or schizoaffective disorder requiring long-term antipsychotic treatment were randomly assigned to open-label oral quetiapine or intramuscular haloperidol decanoate for 48 weeks.
Reversible cerebral atrophy: a case report and literature review.
Uma Thirugnanasampanthan et al.
General hospital psychiatry, 28(5), 458-462 (2006-09-05)
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
Joshua T Kantrowitz et al.
Journal of clinical psychopharmacology, 27(5), 525-526 (2007-09-18)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service